Reports Q4 revenue $22.8M, consensus $44.64M. “We continue to progress our flagship rare disease programs and look forward to sharing ...

Q4 2024 Earnings Call Transcript March 6, 2025 Arcturus Therapeutics Holdings Inc. misses on earnings expectations. Reported ...

Moving on to our ARCT-810 program, this is our messenger RNA therapeutic candidate for ornithine transcarbamylase deficiency. In December 2024, the company initiated dosing of the first OTC ...

N-acetylglutamate synthetase deficiency; OTC, ornithine transcarbamylase deficiency; PCD, pyruvate carboxylase deficiency; PA, propionic acidemia; THAN, transient hyperammonemia of the newborn ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Christian Plank in 2009. Its lead candidate is ETH-OTCD, for Ornithine transcarbamylase deficiency, a rare urea cycle disorder caused by a single defective enzyme. One of the biggest obstacles for ...

Arcturus has advanced the development of ARCT-810, an mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency. In December 2024, the Company initiated dosing of the first OTC ...

As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs ...

ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex ...

The company recently announced promising results from a Phase 1/2 clinical trial conducted by its partner iECURE, which demonstrated a complete clinical response in the first infant dosed for ...